More great news for people with lupus!
The U.S. Food and Drug Administration (FDA) has approved Lupkynis™ (voclosporin) to treat lupus nephritis (lupus-related kidney disease) in adults when used in combination with a background immunosuppressive therapy regimen. Lupkynis is the second new therapy authorized to treat this potentially life-threatening complication of lupus.
Developed by Aurinia Pharmaceuticals, Lupkynis is the first-ever oral therapy for lupus nephritis. Data from extensive clinical studies of Lupkynis showed it had a significantly higher renal response and a faster clinical response over standard of care therapy.
“A new treatment option to fight lupus nephritis, one of the most devastating impacts of lupus, is a significant moment to celebrate,” said Stevan W. Gibson, president and CEO, Lupus Foundation of America. “For a long time, there were no approved treatments for this potentially disabling and life-threatening complication of lupus. We are thrilled that doctors now have a second new option to treat lupus nephritis, which affects up to 60% of people with lupus.”